Senzime

Highlights that Senzime will present at today's digital investor event, which starts at 14:00, includes:

• Senzime aims to become a global leader in patient monitoring to help eliminate anesthesia and respiratory complications. There is now a technology shift in the market that supports new innovative products.
• Sales continue to develop very positively, and YTD May 2023 sales have tripled compared to the same period last year. Driving forces are the US market and the support of new clinical guidelines.
• Sales are largely driven by disposable sensors and increased utilization of the TetraGraph system. The number of disposable sensors sold is estimated to be close to 40,000 in the first half of 2023 - an increase from approximately 15,000 sensors sold in the first half of 2022.
• As of the end of May 2023, the company had 139 hospitals as active customers, compared to 111 at the end of 2022.
• The business objective is to reach a utilization rate that exceeds five TetraSens per TetraGraph per week. The previously communicated financial goals for 2025 stand firm with estimated net sales of SEK 275 - 325 million in 2025, as well as a long-term EBITDA margin that is estimated to exceed 40 percent. Senzimes goal is to reach a market share of at least 10 percent in its active market segments.

"Senzime is now in the middle of the growth phase we have strategically and methodically worked towards. We have a strong focus on the US market, a leading and innovative product portfolio supported by new clinical guidelines, and we are well positioned to continue our growth journey and achieve long-term high profitability", says Philip Siberg, CEO, Senzime.

The presentation will be held in Swedish.

Date and time
Friday, June 2, 2023, at 14.00-15.00

Link:
The investor event is broadcast live via this link: https://www.youtube.com/watch?v=eoKlv_h4otc